Maxim Adjusts Price Target on Apple to $195 From $178
Maxim Starts Coverage on Rani Therapeutics With Buy Rating, $15 Price Target
Maxim Group Keeps Their Hold Rating on SurgePays (SURG)
Maxim Group Downgrades Advanced Human Imaging (AHI) to a Hold
Maxim Group: Upgraded the 5E Advanced Materials (FEAM.US) rating from holding to buying, with a target price of $4.00.
Maxim Group: Downgraded Virpax Pharmaceuticals (VRPX.US) rating from buy to hold
GigaCloud Tech (GCT.US) was first covered by Maxim Group and given a buying rating, with a target price of $69.00.
Maxim Group: Downgraded the rating of Sunshine Dynamics (SPI.US) from buying to holding.
Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Maxim Group Downgrades Biolase (BIOL) to a Hold
Cutera (CUTR) Was Downgraded to a Hold Rating at Maxim Group
Maxim Group: Maintains Sensus Healthcare (SRTS.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $10.00.
Maxim Group: Maintains Hain Celestial Group (HAIN.US) rating, adjusted from buy to buy rating, and adjusted target price from $18.00 to $15.00.
Maxim Group: Maintains Gladstone Land (LAND.US) rating, adjusted from buy to buy rating, and adjusted target price from $19.00 to $16.00.
Maxim Group Reaffirms Their Buy Rating on Inuvo (INUV)
Maxim Adjusts Vivid Seats' Price Target to $9 From $7, Keeps Buy Rating
Maxim Adjusts Ryde Group's Price Target to $9 From $8, Keeps Buy Rating
Maxim Adjusts Beyond's Price Target to $36 From $50, Keeps Buy Rating
Maxim Adjusts Paysign's Price Target to $6 From $5.50, Keeps Buy Rating
No Data